Vision-inducing plants ("hallucinogens") are important in many societies, evoking powerful emotional, psychological, cognitive, religious, spiritual, therapeutic and political reactions. These substances' psychophysiological properties shape cross- cultural similarities in patterns of use and experiences, while political factors shape their cultural desirability. Neurological studies illustrate that common effects are based in intervention in serotonergic neurotransmission. Effects upon neural, sensory, emotional, and cognitive processes stimulate integrative information processing, justifying a new term-"psychointegrators." Psychointegrators disin hibit sensory and emotional processes. They stimulate systemic integration of brain information-processing functions, enhancing integration of limbic system self and emotional dynamics with neocortical processes. Their therapeutic applications are reviewed from perspectives of cross-cultural and clinical studies.
References
1.
Aberle, D. (1966). The Peyote religion among the Navaho. Chicago: Aldine.
2.
Abramson, H. (Ed.). (1967). The use of LSD in psychotherapy and alcoholism. Indianapolis, IN: Bobbs-Merrill.
3.
Aghajanian, G. (1981). The modulatory role of serotonin at multiple receptors in brain. In B. Jacobs & A. Gelperin (Eds.), Serotonin neurotransmission and behavior. Cambridge, MA: MIT Press.
4.
Aghajanian, G. (1982). Neurophysiologic properties of psychotomimetics . In F. Hoffmeister andG. Stille (Eds.), Psychotropic agents III (pp. 89-109). New York: Springer Verlag.
5.
Aghajanian, G. (1984). LSD and serotonergic dorsal raphe neurons: Intracellular studies in vivo and in vitro. In B. Jacobs (Ed.), Hallucinogens: Neurochemical, behavioral and clinical perspectives (pp. 137-141). New York: Raven Press.
6.
Aghajanian, G. (1994). Serotonin and the action of LSD in the brain. Psychiatric Annals, 2463, 137-141.
7.
Alper, K., Lotsof, H., Frenken, G., Luciano, D., & Bastiaans,J. (1999). Treatment of acute opioid withdrawal with ibogaine . American Journal on Addictions, 8(3), 234-242.
8.
Andritzky, W. (1989). Sociopsychotherapeutic functions of ayahuasca healing in Amazonia. Journal of Psychoactive Drugs, 21(1) , 77-89.
9.
Beck, J. (2000). MDMA in the USA: An epidemiological overview. In C. Ratsh & J. Baker (Eds.), Yearbook for Ethnomedicine and the Study of Consciousness, 6/7, 127-136.
10.
Bliss, K. (1988). LSD and psychotherapy. Contemporary Drug Problems, 519-563.
11.
Bravo, G. & Grob, C. (1989). Shamans, sacraments and psychiatrists. Journal of Psychoactive Drugs, 21(1), 123-128.
12.
Burgess,C., O'Donohoe,A. & Gill, M. (2000). Agony and ecstasy: A review of MDMA effects and toxicity. European Psychiatry, 1S(5), 287-94.
13.
Calabrese, J. (1997). Spiritual healing and human development in the Native American Church: Toward a cultural psychiatry of peyote. Psychoanalytic Review, 84(2), 237-255.
14.
Callaway, J. & Grob, C. (1998). Ayahuasca preparations and serotonin reuptake inhibitors: A potential combination for severe adverse interactions. Journal of Psychoactive Drugs, 30(4), 367-369.
15.
Carlsson, A., Waters, N. & Carlsson, M. (1999). Neurotransmitter interactions in schizophrenia-therapeutic implications. European Archives of Psychiatry, 249(4), 37-43.
16.
Cohen, S. (1971). Theories on the effects of psychomimetics. In L. Madow & L. Snow (Eds.), The psychodynamic implications of physiological studies ofpsychomimetic drugs (pp. 3-10). Springfield, IL: Charles Thomas.
17.
Davis, W. (1985). The serpent and the rainbow. New York: Simon & Schuster.
18.
Delgado, P. & Moreno, F. (1998). Hallucinogens, serotonin and obsessive-compulsive disorder. Journal of Psychoactive Drugs, 30(4), 359-366.
19.
Dobkin deRios, M. (1984). Hallucinogens: Cross-cultural perspectives. Albuquerque, NM: University of New Mexico.
20.
Dobkin de Rios, M. & Smith, D. (1977). Drug use and abuse in cross-cultural perspective . Human Organization, 36(1), 14-21.
21.
Fink, M. (1978). Psychoactive drugs and the waking EEG 1966-1976 . In M. Lipton, A. Dimascio, & K. Killam (Eds.), Psychopharmacology (pp. 691-698). New York: Raven Press.
22.
Fischbach, G. (1992, September). Mind and brain. Scientific American, Special Issue, Mind and Brain, 48-57.
23.
Freedman, D. (1984). LSD: The bridge from human to animal. In B. Jacobs (Ed.), Hallucinogens: Neurochemical, behavioral, and clinical perspectives (pp. 203-226). New York: Raven Press.
24.
Furst, P. (Ed.). (1972). Flesh of the gods. New York: Praeger.
25.
Furst, P. (Ed.). (1976). Hallucinogens and culture. San Francisco, CA: Chandler and Sharp.
26.
Glennon, R. (1990). Serotonin receptors: Clinical implications. Neuroscience and Biobehavioral Reviews, 14, 35-47.
27.
Gold, M. (Ed.). (1994a). The new psychedelic subculture. Psychiatric Annals, 24(3).
28.
Gold, M. (1994b). The epidemiology, attitudes and pharmacology of LSD use in the 1990. Psychiatric Annals, 24(3), 124-126.
29.
Greer, G., & Tolbert, R. (1998). A method of conducting therapeutic sessions with MDMA. Journal of Psychoactive Drugs, 30(4), 371-379.
30.
Grob, C., & Dobkin de Rios, M. (1992). Adolescent drug use in cross-cultural perspective. Journal of Drug Issues, 22(1), 121-138.
31.
Grof, S. (1975). Realms of the unconscious: Observations from LSD Research. New York: Viking Press .
32.
Grof, S. (1980). LSD psychotherapy. Pomona, CA: Hunter House.
33.
Grof, S. (1992) The holotropic mind. San Francisco : Harper Collins.
34.
Halpern, J. & Pope, H. (1999). Do hallucinogens cause residual neuropsychological toxicity? Drug & Alcohol Dependence, 53(3), 247-256.
35.
Hamon M. (1984). Common neurochemical correlates to the action of hallucinogens. In B. Jacobs (Ed.), Hallucinogens: Neurochemical, behavioral and clinical perspectives (pp. 143-170). New York: Raven Press.
36.
Harner, M. (Ed.). (1973). Hallucinogens and shamanism. New York: Oxford University Press.
37.
Heggenhougen, C. (1997). Reaching new highs: Alternative therapies for drug addicts. Northvale, NJ: Jason Aronson.
38.
Hoffmeister, F. & Stille, G. (Eds.). (1982). Psychotropic agents III . New York: Springer Verlag.
39.
Hollister, L. (1984). Effects of hallucinogens in humans. In B. Jacobs (Ed.), Hallucinogens: Neurochemical, behavioral and clinical perspectives (pp. 203-226). New York: Raven Press.
40.
Jacobs, B. (1984a). (Ed.). Hallucinogens: Neurochemical, behavioral, and clinical perspectives. New York: Raven Press.
41.
Jacobs, B. (1984b). Postsynaptic serotonergic action of hallucinogens . In B. Jacobs (Ed.), Hallucinogens: Neurochemical, behavioral, and clinical perspectives, (pp. 183-202). New York: Raven Press.
42.
Jacobs, B., & Gelperin, A. (Eds.). (1981). Serotonin neurotransmission and behavior. Cambridge, MA: MIT Press.
43.
Jacobs, B. & Trulson, M. (1981). The role of serotonin in the action of hallucinogenic drugs. In B. Jacobs & A. Gelperin (Eds.), Serotonin neurotransmission and behavior. Cambridge, MA: MIT Press.
44.
Jacobs, D. (1996). The use of Datura in rites of transition. In M. Winkelman & W. Andritsky (Eds.), Sacred plants, consciousness and healing (pp. 341-351).
45.
Yearbook of cross-cultural medicine and psychotherapy, 5. Berlin: VWB.
46.
Jilek, W. (1994). Traditional healing and the prevention and treatment of alcohol and drug abuse. Transcultural Psychiatric Research Review, 31, 219-258.
47.
Kruk, Z. & Pycock, C. (1991). Neurotransmitters and drugs. London: Chapman and Hall.
48.
Kurland, A. (1985). LSD in the supportive care of the terminally ill cancer patient. Journal of Psychoactive Drugs, 17 (4), 279-290.
49.
La Barre, W. (1970). Old and New World narcotics: A statistical question . Economic Botany, 24, 368-373.
50.
La Barre, W. (1972). Hallucinogens and the shamanic origins of religion . In P. Furst (Ed.), Flesh of the gods (pp. 261-278). New York: Praeger .
51.
Laughlin, C., McManus, J. & d'Aquili, E. (1992). Brain, symbol and experience toward a neurophenomenology of consciousness. New York: Columbia University Press.
52.
Leary, T. (1997). Psychedelic prayers and other meditations. Berkeley, CA: Ronin Publishing Co.
53.
Lukoff, D., Zanger, R. & Lu, F. (1990). Transpersonal psychology research review: Psychoactive substances and transpersonal states. Journal of Transpersonal Psychology, 22(2), 107-147.
54.
Mabit, J., Giove R. & Vega J. (1996). Takiwasi: The use of Amazonian shamanism to rehabilitate drug addicts. In M. Winkelman & W. Andritzky (Eds.), Sacred plants, consciousness and healing. Yearbook of Cross-Cultural Medicine and Psychotherapy, 5 (pp. 257-85). Berlin: VWB.
55.
MacLean, P. (1990). The triune brain in evolution. New York: Plenum.
56.
Mandell, A. (1980). Toward a psychobiology of transcendence: God in the brain. In D. Davidson andR. Davidson (Eds.), The psychobiology of consciousness (pp. 379-464). New York: Plenum.
57.
Mandell, A. (1985). Interhemispheric fusion. Journal of Psychoactive Drugs, 17(4), 257-266.
58.
Mangini, M. (1998). Treatment of alcoholism using psychedelic drugs: A review of the program of research. Journal of Psychoactive Drugs, 30(4), 381-418.
59.
Mathias, R. (1993). NIDA research takes a new look at LSD and other hallucinogens. NIDA Notes, 8(1), 6-11.
60.
McKim, W. (1991). Drugs and behavior: An introduction to behavioral pharmacology. Englewood Cliffs, NJ:Prentice-Hall.
61.
Metzner, R. (1998). Hallucinogenic drugs and plants in psychotherapy and shamanism. Journal of Psychoactive Drugs, 30 (4), 333-431.
62.
Miller, N. & Gold, M. (1993). LSD and ecstasy: Pharmacology, phenomenology and treatment. Psychiatric Annals, 24(3), 131-134.
63.
Naranjo, C. (1996). The interpretation of psychedelic experience in light of the psychology of meditation. In M. Winkelman & W. Andritsky (Eds.), Sacred plants, consciousness and healing (pp. 75-90).
64.
Yearbook of Cross-Cultural Medicine and Psychotherapy, 5. Berlin: VWB.
65.
Ott, J. ( 1993). Pharmacotheon. Kennewick, WA: Natural Products.
66.
Ott, J. ( 1994). Ayahuasca analogues. Kennewick, WA : Natural Products.
67.
Parent, A. (1981). The anatomy of serotonin-containing neurons across the phylogeny. In B. Jacobs & A. Gelperin (Eds.), Serotonin neurotransmission and behavior. Cambridge, MA: MIT Press.
68.
Parrott, A., Sisk, E., & Turner, J. (2000). Psychobiological problems in heavy "ecstasy" (MDMA) polydrug users. Drug & Alcohol Dependence, 60(1), 105-110.
69.
Passie, T. (1997). Psycholytic and psychedelic therapy research, 1931-1995: A complete international bibliography. Hannover , Germany: Laurentius Publishers.
70.
Praag, H. (1991). The present and future of serotonergic drugs. Human Psychopharmacology, 6, 513-519.
71.
Rätsch, C. (Ed.). (1989). Gateway to inner space, sacred plants, mysticism and psychotherapy. Bridgeport, Dorset: Prisim Press.
72.
Ribeiro, C. (1991). Pharmacology of serotonin neuronal systems. Human Psychopharacology, 6, 37-51.
73.
Riedlinger, T. & Riedlinger, J. (1994). Psychedelic and entactogenic drugs in the treatment of depression. Journal of Psychoactive Drugs, 26(1), 41-55.
74.
Roberts, T. (1999). Do entheogen-induced mystical experiences boost the immune system? Psychedelics, peak experiences, and wellness. Advances in Mind-Body Medicine, 15, 139-147.
75.
Roberts, T. (Ed.). (2000). Psychoactive sacraments. San Francisco: Council on Spiritual Practices.
76.
Role, L., & J. Kelly. (1991). The brain stem: Cranial nerve nuclei and the monoaminergic systems. In E. Kandal , J. Schwartz & T. Jessell (Eds.), Principles of neural science , (pp. 683-699). New York: Elsevier.
77.
Ryall, R. (1989). Mechanisms of drug action on the nervous system . Cambridge, UK: Cambridge University Press.
78.
Sanchez-Ramos, J., & Mash, D. (1996). Pharmacotherapy of drug dependence with ibogain . In M. Winkelman & W. Andritzky (Eds.), Sacred plants, consciousness and healing. Yearbook of Cross-Cultural Medicine and Psychotherapy, 5, 353-367. Berlin: VWB.
79.
Schmidt, A., & Peroutka, S. (1989). S-Hydroxytryptamine Receptor "Families." Neuropsychopharmacology, 3, 2242-2249.
80.
Schultes, R. (1972). An overview of hallucinogens in the western hemisphere . In P. Furst (Ed.), Flesh of the gods, (pp. 3-54). New York: Praeger .
81.
Schultes, R., & Hofmann, A. (1979). Plants of the gods origins of hallucinogenic use . New York: McGraw Hill. (Reprinted 1992 by Healing Arts Press, Rochester, Vermont)
82.
Schultes, R., & Winkelman, M. (1996). The principal American hallucinogenic plants and their bioactive and therapeutic properties. In M. Winkelman & W. Andritsky (Eds.), Sacred plants, consciousness and healing (pp. 205-239).
83.
Yearbook of Cross-Cultural Medicine and Psychotherapy, 5. Berlin: VWB.
84.
Schuster, P., Lieb, R.Lamertz, C. & Wittchen, H. (1998). Is the use of ecstasy and hallucinogens increasing? Results from a community study. European Addiction Research , 4(1-2),75-82.
85.
Shannon, B. (2000). Cognitive psychology and the study of Ayahuasca , In C. Ratsch & J. Baker (Eds.), Yearbook for Ethnomedicine and the Study of Consciousness, 6/7, 77-94.
86.
Shulgin, A., & Shulgin, A. (1995). Phikal. Berkeley, CA: Transform Press.
87.
Siegel, R. (1984). The natural history of hallucinogens. In B. Jacobs (Ed.), Hallucinogens : Neurochemical, behavioral and clinical perspectives (pp. 1-18). Raven Press: New York.
88.
Siegel, R. (1990). Intoxication: Life in pursuit of artificial paradise . New York: Dutton.
89.
Smith, D., & Seymour, R. (1994). LSD: History and toxicity. Psychiatric Annals, 24(3), 145-147.
90.
Smith, H. (2000). Cleansing the doors of perception: The religious significance of enthenogenic plants and chemicals. New York: J. P. Tarcher.
91.
Stafford, P. (1992). Psychedelics encyclopedia. Berkeley, CA: Ronin Press.
92.
Wasson, R., Kramrisch, S., Ott, J. & Ruck, C. (1986). Persephone's quest: Ethnogens and the origins of religion. New Haven, CT: Yale University Press.
93.
Wasson, R. (1980). The wondrous mushroom: Mycolatry in Mesoamerica . New York: McGraw Hill.
94.
Werner M. (1993) Hallucinogens. Pediatrics in Review , 14(12), 466-472.
95.
Winkelman, M. (1986a). Trance states: A theoretical model and cross-cultural analysis. Ethos, 14(2), 174-203.
96.
Winkelman, M. (1986b). Magico-religious practitioner types and socioeconomic conditions. Behavior Science Research, 20, 17-46.
97.
Winkelman, M. (1990). Shaman and other "magico-religious" healers: A cross-cultural study of their origins, nature, and social transformations . Ethos, 18, 308-352.
98.
Winkelman, M. (1991). Physiological, social and functional aspects of drug and non-drug altered states of consciousness. In W. Andritzky (Ed.), Yearbook of cross-cultural medicine and psychotherapy, 1990 (pp. 183-198). Berlin: VWB-Verlag.
99.
Winkelman, M. (1992). Shamans, priests and witches. A cross-cultural study of magico-religious practitioners (Anthropological Research Papers #44 . Arizona State University.
100.
Winkelman, M. (1996). Psychointegrator plants: Their roles in human culture and health. In M. Winkelman & W. Andritzky (Eds.), Sacred plants, consciousness and healing. Yearbook of cross-cultural medicine and psychotherapy, 5 (pp. 9-53). Berlin : VWB.
101.
Winkelman, M. (2000). Shamanism: The neural ecology of consciousness and healing. Westport, CT: Bergin & Garvey.
102.
Winkelman, M., & Andritzky, W. (Eds.). (1996). Sacred plants, consciousness and healing. Yearbook of cross-cultural medicine and psychotherapy , 5. Berlin : VWB .
103.
Yensen, R. (1985). LSD and psychotherapy. Journal of Psychoactive Drugs, 17(4), 267-277.
104.
Yensen, R. (1996). From shamans and mystics to scientists and psychotherapists . In M. Winkelman & W. Andritzky (Eds.), Sacred plants, consciousness and healing. Yearbook of cross-cultural medicine and psychotherapy (Vol. 5, pp. 109-128). Berlin: VWB.
105.
Zanger, R. (1989). Psycholytic therapy in Europe. Newsletter: The Albert Hoffman Foundation, 1(2).
106.
Zoccolillo, M., Vitaro, F., & Tremblay, R. (1999). Problem drug and alcohol use in a community sample of adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 38(7), 900-907.
